NCT05431270View on ClinicalTrials.gov

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

40

Participants

Timeline

Start Date

August 11, 2022

Primary Completion Date

December 31, 2027

Study Completion Date

August 31, 2028

Conditions

Non Small Cell Lung CancerPancreatic Ductal Adenocarcinoma

Interventions

DRUG

Mavrostobart (PT199)

Mavrostobart (PT199) is an anti-CD73 mAb with a differentiated mechanism of action.

DRUG

Tislelizumab

Anti-PD-1 monoclonal antibody 200 mg Q3W, inhibits the lymphocytes PD-1 receptors, blocking the ligands that would deactivate it and prevent an immune response.

DRUG

Gemcitabine + nab-Paclitaxel

Dosing is per Standard of Care.

DRUG

Docetaxel

Dosing is per Standard of Care.

DRUG

Pemetrexed

Dosing is per Standard of Care.

DRUG

Gemcitabine

Dosing is per Standard of Care.

DRUG

Carboplatin + Pemetrexed

Dosing is per Standard of Care.

DRUG

Pembrolizumab + Carboplatin + Pemetrexed

Dosing is per Standard of Care.

Trial Locations (6)

22031

RECRUITING

NEXT Oncology, Fairfax

28078

RECRUITING

Carolina BioOncology Institute, Huntersville

37203

RECRUITING

SCRI Oncology Partners, Nashville

73104

RECRUITING

Sarah Cannon Research Institute University of Oklahoma, Oklahoma City

77030

RECRUITING

The University of Texas MD Anderson Cancer Center, Houston

77598

RECRUITING

Tranquility Research, Webster

Sponsors

Lead Sponsor

Phanes Therapeutics

Collaborators (1)

All Listed Sponsors

collaborator

BeiGene

INDUSTRY

lead

Phanes Therapeutics

INDUSTRY

NCT05431270 - Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study) | Biotech Hunter | Biotech Hunter